Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.

Patrick W G Mallon1, Andrew Carr, David A Cooper

  • 1National Centre in HIV Epidemiology and Clinical Research, St. Vincent's Hospital Medical Centre, 376 Victoria Street, Sydney NSW 2010, Australia. pmallon@nchecr.unsw.edu.au

Current Diabetes Reports
|March 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Less frequent clinical and viral load assessments during COVID did not increase virological failure.

International journal of STD & AIDS·2026
Same author

Measuring Value in Orthopaedics: The U.S. and U.K. Perspectives.

The Journal of bone and joint surgery. American volume·2026
Same author

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Lancet (London, England)·2026
Same author

Translational Potential of an Electrospun Polycaprolactone Scaffold for Anterior Cruciate Ligament Reconstruction.

Advanced fiber materials·2026
Same author

Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings.

BMJ open·2025
Same author

Anal cancer screening in men who have sex with men living with HIV: The pilot of anal screening study (PASS).

HIV medicine·2025
Same journal

Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.

Current diabetes reports·2026
Same journal

Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.

Current diabetes reports·2026
Same journal

Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions.

Current diabetes reports·2026
Same journal

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.

Current diabetes reports·2026
Same journal

Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.

Current diabetes reports·2026
Same journal

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.

Current diabetes reports·2026
See all related articles

Antiretroviral drugs for HIV can cause body shape changes and metabolic issues, known as HIV-associated lipodystrophy. These metabolic problems increase cardiovascular disease risk in HIV patients, and standard treatments are often less effective.

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Pharmacology

Background:

  • Antiretroviral therapy (ART) is crucial for managing HIV infection.
  • HIV-infected individuals on ART may develop HIV-associated lipodystrophy (HIVLD).
  • HIVLD involves changes in body composition and metabolic disturbances.

Purpose of the Study:

  • To investigate the effects of antiretroviral medications on organ function in HIV patients.
  • To understand the mechanisms behind HIVLD.
  • To assess the cardiovascular disease risk associated with HIVLD.

Main Methods:

  • In vitro and in vivo studies were conducted.
  • The research examined the impact of protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs).

Related Experiment Videos

  • Organ function, particularly in adipose tissue, liver, and muscle, was assessed.

    • Main Results:

    • Protease inhibitors and nucleoside reverse transcriptase inhibitors significantly affect adipose tissue, liver, and muscle function.
    • Metabolic abnormalities, including dyslipidemia and insulin resistance, are associated with HIVLD.
    • These metabolic changes contribute to an elevated risk of cardiovascular disease.

    Conclusions:

    • Antiretroviral medications can induce significant metabolic changes and lipodystrophy in HIV patients.
    • HIVLD poses a substantial cardiovascular risk in this population.
    • Current treatment strategies for metabolic abnormalities are often less effective in HIVLD patients due to ongoing ART effects.